OncoPharm cover image

NAPOLI 3, POUT, & Ivosidenib - Azole DDIs

OncoPharm

00:00

Trial results and statistical versus clinical significance

John presents median OS (11.1 vs 9.2 months), HR 0.83, and contrasts statistical significance with modest clinical benefit.

Play episode from 06:26
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app